Alembic Pharmaceuticals announces USFDA Final Approval for Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg

Alembic Pharmaceuticals Limited (Alembic) today announced it has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), ProAmatine Tablets, 2.5 mg, 5 mg, and 10 mg, of Takeda Pharmaceuticals USA, Inc. (Takeda). Midodrine Hydrochloride Tablets are indicated for the treatment of symptomatic orthostatic hypotension (OH). Midodrine Hydrochloride Tablets USP 2.5 mg, 5 mg, and 10 mg have an estimated. the market size of US$ 60 million for twelve months ending September 2020 according to IQVIA. Alembic has a cumulative total of 138 ANDA approvals (120 final approvals and 18 tentative approvals) from USFDA.